Image commercially licensed from Unsplash

The remarkable journey of New York Cryogen and its visionary founder, Gregory Papageorge, stands as a beacon of hope and a testament to the power of human ingenuity. Through their pioneering work in the field of high-pressure medical cryotherapy, they are on the cusp of revolutionizing pain relief and offering new possibilities for individuals suffering from chronic pain.

A Personal Quest Turns into a Revolution

New York Cryogen, the harbinger of change in the realm of pain management, had its humble beginnings in November 2021 when Gregory Papageorge embarked on a personal quest to find a solution for his own pain management needs. Unbeknownst to him at the time, this seemingly modest pursuit would pave the way for a medical revolution of unparalleled proportions.

At the core of this journey lies Papageorge’s acquisition of a small medical device, initially intended to alleviate his own pain. But as he delved into the functionality of this unassuming device, he quickly recognized its shortcomings. It was this very astute recognition that would lead to a groundbreaking innovation in the field of pain relief.

Traditional cryotherapy, while effective in some cases, had long been hampered by its limited ability to penetrate deep into body tissues. Gregory Papageorge’s revolutionary approach involved pressurizing cryogenic gas and administering it directly to the body. This innovative twist to the conventional cryotherapy method not only provided profound pain relief but also facilitated almost immediate reduction of inflammation, setting the stage for a monumental shift in pain management.

Enhancing Safety and Effectiveness

New York Cryogen’s commitment to patient safety and comfort has been unwavering, resulting in a significant enhancement in their high-pressure cryotherapy treatments. In an industry where skin protection is paramount, the company introduced the use of 3M Tegaderm and Ioban to mitigate skin-related issues that patients had been experiencing.

Patient feedback, which highlighted skin irritation and stinging despite manufacturer claims to the contrary, became the catalyst for this critical development. The addition of protective sheathing over the skin not only effectively mitigated the shock of cold exposure but also reduced the risk of burns and irritations. The occurrence of skin irritation has since dropped to less than 1%, a remarkable testament to the dedication of New York Cryogen to patient safety.

Moreover, the company’s innovative approach addressed another issue often overlooked in the industry – condensation buildup on the skin, particularly in humid environments. Condensation interacting with cold gas, such as liquid carbon dioxide, can lead to “rain” or condensation, causing ice burns. Thankfully, the sheathing material utilized by New York Cryogen is waterproof, ensuring rigorous treatment while allowing the cryo-gas to penetrate. This material is also cryo-lucent, ensuring the transparency required for accurate treatment.

To further enhance safety and comfort, New York Cryogen has partnered with a NASA structural engineer to develop a state-of-the-art reusable sheathing material infused with nano-technology. This material has the remarkable ability to self-regulate, automatically restricting the passage of cryo-gas when it reaches a predetermined temperature. Although this innovation is still in the developmental phase, its potential for eliminating the disposable nature of existing products and optimizing the efficiency of the AC-130 Viper system is undeniably promising.

The Visionary Behind the Revolution

At the heart of this groundbreaking innovation is the visionary Gregory Papageorge, whose impressive 24-year career in healthcare sales has been instrumental in driving change. With expertise spanning the intricate landscapes of biotech pharmaceuticals and medical devices, Papageorge’s focus on complex spine solutions over the past 15 years provided him with a unique perspective on pain management. This wealth of experience formed the bedrock upon which the foundations of New York Cryogen were laid.

The significance of high-pressure medical cryotherapy lies in its exceptional ability to penetrate tissues effectively, targeting the root cause of pain and inflammation. Mr. Papageorge’s vision has not only led to the endorsement of this revolutionary approach by the American Medical Association (AMA) but has also marked a historic moment in the world of cryotherapy.

A Pioneer in Health Insurance

New York Cryogen has achieved another remarkable milestone by becoming the first cryotherapy company capable of accepting healthcare insurance for high-pressure cryotherapy treatments. This accomplishment goes beyond providing pain management; it empowers individuals to become certified medical providers for this transformative modality.

A Future of Possibilities

New York Cryogen’s vision reaches far beyond pain management alone. The company is deeply committed to developing medical devices for high-pressure cryotherapy, with the AC-130 Viper leading the way as the first of its kind globally. Three additional devices are currently in development, promising even more groundbreaking innovations in the field. Their leap in technology has already been recognized by Medicare, Medicaid, and private insurance providers, with integration underway in seven states. A national expansion is planned for 2023 and 2024, including Hawaii and Puerto Rico. The company’s ambition extends internationally as well, with a goal to introduce this revolutionary technology in Canada, the United Kingdom, and other European countries within a year.

The technology created by Gregory Papageorge and New York Cryogen has the potential to reshape not only the cryotherapy industry but also the broader field of medicine. The AMA’s unanimous fast-track approval of this innovative modality underscores its significance in pain management and affirms its safety and efficacy.

A Testimony to Success

Clinical and observational trials conducted by Mr. Papageorge himself have provided compelling evidence of the technology’s effectiveness. In less than two years, over 6,500 procedures have been completed, showcasing the rapid impact and numerous benefits it offers. The AMA’s resounding approval of this modality is a powerful testament to its potential to transform pain management.

As we stand on the threshold of a medical revolution, Gregory Papageorge and New York Cryogen invite you to join them on a journey to explore high-pressure medical cryotherapy. This groundbreaking technology holds the potential to reshape the cryotherapy industry and improve the lives of countless individuals in need of pain relief and healing.

In the face of pain, New York Cryogen and Gregory Papageorge offer a beacon of hope through innovation, revolutionizing the path to relief and recovery. Their commitment to improving lives has the potential to reshape the future of pain management, setting a new standard that will inspire individuals and professionals alike to explore the possibilities of high-pressure medical cryotherapy.

Stay updated on their groundbreaking innovations by following New York Cryogen on Instagram (newyorkcryogen) and Facebook (New York Cryogen). Visit their website at www.nycryogen.com &  www.ac130viper.com to learn more about their products and services.